Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

CHEK2 screening: do not think so globally yet.

Iniesta MD, Merajver SD.

J Clin Oncol. 2008 Jun 20;26(18):3092; author reply 3093-4. doi: 10.1200/JCO.2008.16.9151. No abstract available.

PMID:
18565899
2.

CHEK2*1100delC screening of Asian women with a family history of breast cancer is unwarranted.

Lee AS, Ang P.

J Clin Oncol. 2008 May 10;26(14):2419; author reply 2419-20. doi: 10.1200/JCO.2008.16.4335. No abstract available.

PMID:
18467741
3.

CHEK2*1100delC does not contribute to risk to breast cancer among Malay, Chinese and Indians in Malaysia.

Thirthagiri E, Cheong LS, Yip CH, Teo SH.

Fam Cancer. 2009;8(4):355-8. doi: 10.1007/s10689-009-9244-x. Epub 2009 Apr 28.

PMID:
19399639
4.

CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.

Weischer M, Bojesen SE, Ellervik C, Tybjaerg-Hansen A, Nordestgaard BG.

J Clin Oncol. 2008 Feb 1;26(4):542-8. doi: 10.1200/JCO.2007.12.5922. Epub 2008 Jan 2. Review.

PMID:
18172190
5.

CHEK2 mutation and hereditary breast cancer.

Narod SA, Lynch HT.

J Clin Oncol. 2007 Jan 1;25(1):6-7. Epub 2006 Nov 28. No abstract available.

PMID:
17132696
6.

CHEK2 mutation and hereditary breast cancer.

Bogdanova N, Feshchenko S, Cybulski C, Dörk T.

J Clin Oncol. 2007 Jul 1;25(19):e26. No abstract available.

PMID:
17602067
7.

Does breast cancer associated with CHEK2 1100delC carry characteristics of basal phenotype?

Dede DS, Sari E, Bulut N, Altundag K.

Breast Cancer Res Treat. 2007 Jul;103(3):371. Epub 2006 Oct 25. No abstract available.

PMID:
17063273
8.

Absence of CHEK2 mutations in Spanish families with hereditary breast cancer.

Bellosillo B, Tusquets I, Longarón R, Pérez-Lezaun A, Bellet M, Fabregat X, Serrano S, Solé F.

Cancer Genet Cytogenet. 2005 Aug;161(1):93-5. No abstract available.

PMID:
16080966
9.

Absence of CHEK2 1100delC mutation in familial breast cancer cases from a South American population.

González-Hormazábal P, Castro VG, Blanco R, Gómez F, Peralta O, Waugh E, Bravo T, Reyes JM, Jara L.

Breast Cancer Res Treat. 2008 Aug;110(3):543-5. Epub 2007 Sep 18. No abstract available.

PMID:
17876702
10.

CHEK2 1100delC is present in familial breast cancer cases of the Basque Country.

Martínez-Bouzas C, Beristain E, Guerra I, Gorostiaga J, Mendizabal JL, De-Pablo JL, García-Alegría E, Sanz-Parra A, Tejada MI.

Breast Cancer Res Treat. 2007 May;103(1):111-3. Epub 2006 Oct 25. No abstract available.

PMID:
17063278
11.

Breast cancer low-penetrance allele 1100delC in the CHEK2 gene: not present in the Chinese familial breast cancer population.

Chen W, Yurong S, Liansheng N.

Adv Ther. 2008 May;25(5):496-501. doi: 10.1007/s12325-008-0057-3.

PMID:
18484200
12.

Germline CHEK2*1100delC mutations in breast cancer patients with multiple primary cancers.

Huang J, Domchek SM, Brose MS, Rebbeck TR, Nathanson KL, Weber BL.

J Med Genet. 2004 Nov;41(11):e120. No abstract available.

13.

A novel germline CHEK2 deletion truncating the kinase domain identified in a French family with high-risk of breast/ovarian cancer.

Escudie P, Monteil-Onteniente S, Gladieff L, Feillel V, Guimbaud R, Favre G, Toulas C.

Breast Cancer Res Treat. 2010 Feb;120(1):267-70. doi: 10.1007/s10549-009-0551-6. Epub 2009 Sep 19. No abstract available.

PMID:
19768534
14.

A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland.

Cybulski C, Wokołorczyk D, Huzarski T, Byrski T, Gronwald J, Górski B, Debniak T, Masojć B, Jakubowska A, van de Wetering T, Narod SA, Lubiński J.

Breast Cancer Res Treat. 2007 Mar;102(1):119-22. Epub 2006 Aug 8.

PMID:
16897426
15.

Irrelevance of CHEK2 variants to diagnosis of breast/ovarian cancer predisposition in Polish cohort.

Myszka A, Karpinski P, Slezak R, Czemarmazowicz H, Stembalska A, Gil J, Laczmanska I, Bednarczyk D, Szmida E, Sasiadek MM.

J Appl Genet. 2011 May;52(2):185-91. doi: 10.1007/s13353-010-0013-1. Epub 2010 Dec 1.

PMID:
21120647
16.

The CHEK2 gene and inherited breast cancer susceptibility.

Nevanlinna H, Bartek J.

Oncogene. 2006 Sep 25;25(43):5912-9. Review.

PMID:
16998506
17.

Synergistic interaction of variants in CHEK2 and BRCA2 on breast cancer risk.

Serrano-Fernández P, Debniak T, Górski B, Bogdanova N, Dörk T, Cybulski C, Huzarski T, Byrski T, Gronwald J, Wokołorczyk D, Narod SA, Lubiński J.

Breast Cancer Res Treat. 2009 Sep;117(1):161-5. doi: 10.1007/s10549-008-0249-1. Epub 2008 Nov 22.

PMID:
19030985
18.

The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.

Oldenburg RA, Kroeze-Jansema K, Kraan J, Morreau H, Klijn JG, Hoogerbrugge N, Ligtenberg MJ, van Asperen CJ, Vasen HF, Meijers C, Meijers-Heijboer H, de Bock TH, Cornelisse CJ, Devilee P.

Cancer Res. 2003 Dec 1;63(23):8153-7.

19.

[Press, ethics and genetic screening].

Gerdes AM, Brøndum-Nielsen K, Ejlertsen B.

Ugeskr Laeger. 2006 Oct 2;168(40):3448; author reply 3448. Danish. No abstract available.

PMID:
17039600
20.

Increased risk of breast cancer associated with CHEK2*1100delC.

Weischer M, Bojesen SE, Tybjaerg-Hansen A, Axelsson CK, Nordestgaard BG.

J Clin Oncol. 2007 Jan 1;25(1):57-63. Epub 2006 Jul 31.

PMID:
16880452

Supplemental Content

Support Center